一种重组抗体及其制备方法
- 专利权人:
- 广州市鲁诚生物科技有限公司
- 发明人:
- 于志军,张希涛,韩艳萍
- 申请号:
- CN201711460744.1
- 公开号:
- CN107880129A
- 申请日:
- 2017.12.28
- 申请国别(地区):
- 中国
- 年份:
- 2018
- 代理人:
- 李新梅`杨昕昕
- 摘要:
- 本发明涉及生物制药领域,具体公开了一种重组抗体及其制备方法。所述的重组抗体,包括两条重链和两条轻链,(1)重链可变区,包含以下重链CDR氨基酸序列:SEQ ID NO:1,SEQ ID NO:2,SEQ ID NO:3;(2)轻链可变区,包含以下轻链CDR氨基酸序列:SEQ ID NO:4,SEQ ID NO:5,SEQ ID NO:6。该重组抗体由包含SEQ ID NO:7和SEQ ID NO:8所述的核苷酸序列编码而成。所述的重组抗体,可以非常有效的抑制A431和HUVEC肿瘤细胞的增长,对HUVEC肿瘤细胞的抑制率是Avastin的近4倍,具有非常显著的抑制效果。
- 来源网站:
- 中国工程科技知识中心
相关发明人
相关专利
- RECOMBINANT ANTIBODIES AGAINST THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF) OBTAINED BY VARIABLE REGION MUTAGENESIS
- Recombinant antibody against vascular endothelial growth factor (VEGF) obtained by mutagenesis of variable region
- Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions
- Recombinant Antibodies against vascular endothelial growth factor (VEGF) obtained by mutagenesis of variable regions.
- RECOMBINANT ANTIBODIES AGAINST THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF) OBTAINED BY VARIABLE REGION MUTAGENESIS